OmniAb, Inc. (OABI)
Nasdaq · Healthcare · Biotechnology
$4.92+1.03%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $715M
- 52-week range
- $1.30 – $5.43
- 52-week change
- +189.88%
- EPS (trailing)
- −$0.36
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $18.7M (−29.27%)
- Net income
- −$64.8M
- Operating margin
- −369.5%
- Diluted EPS
- −$0.57
- Free cash flow
- −$37.0M
From the company’s annual report on SEC EDGAR.
About OmniAb, Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Headquarters: EmeryVille, United States · 89 employees · omniab.com